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Neural Tube Defects and 19 bp Deletion Within Intron-1
of Dihydrofolate Reductase Gene
Aims: Dihydrofolate reductase (DHFR) is necessary for the reduction of the ingested folates before they are
used in the body metabolism. Thus, the DHFR enzyme has an important role in folate supplementation and
the DHFR gene is a strong candidate for a teratogenic locus for neural tube defects (NTDs). There is a 19 bp
deletion within the first intron of the DHFR gene, which may have an effect on folate reduction. We thus
studied this mutation in Turkish spina bifida patients and their mothers to determine whether there is an
association with the occurrence of NTD.
Materials and Methods: The case-control study included 69 meningomyelocele (MMC) patients and 104
mothers who gave birth to NTD babies. One hundred sixty eight women, consecutively selected, who admitted
to the laboratory, were included as controls. One hundred thirty-six newborns without MMC were also
included.
Results: DHFR gene 19 bp deletion in homozygous state was significantly higher in the MMC group compared
to control newborns [Odds Ratio 2.4 (CI 95% 0.95-6.08)]. It also brought 2.4- fold risk [Odds Ratio 2.4 (CI
95% 1.04-5.6)] in NTD mothers compared to controls.
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Conclusions: Our data revealed that DHFR gene 19 bp deletion homozygosity and other possible mutations
in the DHFR gene should be studied further especially in folate-supplemented mothers with NTD recurrence.
Key Words: Neural tube defects, spina bifida, dihydrofolate reductase

Neural Tüp Defektleri ve Dihidrofolat Redüktaz Geni
İntron-1’de Yer Alan 19 bp’lik Delesyon
Amaç: Dihidrofolat redüktaz folatın indirgenmesinde rol alan bir enzimdir. Bu nedenle folat suplementasyonu
yapılması halinde önem kazanmaktadır. Özellikle neural tüp defektlerinde önemi olan folatın, annelere
supplementasyonunda önemli rol oynayabilir. DHFR geninin birinci intronunda 19 bp’lik bir delesyon
bulunmaktadır. Bu delesyon folat indirgenmesinde rolü olabilecek bir gen değişimidir.
Yöntem ve Gereç: Vaka-kontrol şeklinde tasarımlanan çalışmamızda, 69 meningomyleoselli olgu ile 104
NTD’li bebek sahibi olmuş anneler ile 168 sağlıklı kadın ile 136 yenidoğan çalışmaya alınmışlardır. Çalışmaya
alınan bireylerde ve/veya ebeveynlerinden yazılı onay alınmıştır.
Bulgular: DHFR geni 19 bp delesyonunu homozigot olarak taşıma oranı MMS’li olgularda yenidoğan sağlıklı
bebeklere oranla daha yüksek bulunmuştur [Odds Ratio 2.4 (CI 95 % 0.95 -6.08)]. Anneler içinde 2.4 kat
risk getirmektedir [OR 2.4 (CI 95 % 1.04-5.6)].
Sonuç: Verilerimiz, folat supplemenatsayonundan yarar görmeyen NTD’li bebek doğurmuş annelerde önemli
bir gen olarak görülmüş ve ileri araştırmalar için iyi bir aday gen olabileceği düşüncesine ulaşılmıştır.
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Introduction
Meningomyelocele (MMC), encephalocele and anencephaly are the most common
severe congenital malformations of the central nervous system (CNS). These
malformations arise due to failure of closure of the neural tube and are referred to as
neural tube defects (NTDs), with high incidence in some parts of the world, including
Turkey (incidence is 4 in 1000 live births). NTD causation is believed to be multifactorial,
with genetic and environmental components (1,2). The relationship between
periconceptional dietary folate supplementation and the prevention of up to
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approximately 70% of NTDs is well recognized, although
the mechanisms underlying the beneficial effect of folate
are only partly understood (3).
There is a growing interest in the relationship
between variation in genes that are involved in the folatehomocysteine metabolic pathway and the risk of spina
bifida. The evaluation of this relationship is, however,
complicated by the potential involvement of both the
maternal and the embryonic genotype in determination of
disease risk.
Our group and others have published data on
homocysteine metabolism-related polymorphisms in
patients with spina bifida and their mothers in different
populations. Although the data varies among study
groups, our data revealed that none of the common risk
mutations in three genes (methylenetetrahydrofolate
reductase (MTHFR) 677C-T and 1298 A-C, methionine
synthase (MS) 2756 A-G, and cystathionine B-synthase
(CBS) Exon 8, 844 Ins 68), either alone or in
combination, increased the risk for the occurrence of
spina bifida in our population (4,5).
Homocysteine (Hcy) accumulation can be due to
dietary (e.g. low folate), environmental or genetic factors
and is mildly elevated in some pregnant women who
subsequently give birth to infants with NTDs (6). Partial
prevention of recurrence of NTDs including spina bifida
was found for mothers taking multivitamins containing
folic acid during pregnancy (7,8).
It is logical that genes that mediate absorption of
ingested folate and genes that metabolize folate to forms
required for cellular metabolism are candidates for
teratogenic loci.
Dihydrofolate reductase (DHFR) has a key role in
folate biosynthesis and is responsible for the generation
of the DNA base, deoxythymidine monophosphate. DHFR
is also involved in the biosynthesis of purine nucleotides
and the amino acids histidine and methionine. Humans do
not have the ability to synthesize folates de novo and
instead use a membrane-bound reduced folate carrier to
bring dietary folic acid, which is then reduced to
tetrahydrofolate by DHFR into the cell (9).
Johnson et al. (10) (2004) proposed the DHFR gene
as a strong candidate for a teratogenic locus because
ingested folates must be fully reduced by the enzyme
before being used in the body metabolism. All of the
folate from vitamin supplements and food fortification is
384
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folic acid, a form of folate that is unreduced and requires
the action of DHFR before it can participate in cellular
reactions. The DHFR gene, synthesizing the DHFR
enzyme, is a genetic factor that is well placed to interact
with the environmental component of the folate risk
factor for adverse pregnancy outcome, i.e., dietary
folates and folic acid supplements. Human cells also
depend on DHFR for DNA replication, a crucial feature of
gestation and development. Johnson et al. also reported
a polymorphic 19 bp deletion within intron-1 of DHFR,
hypothesizing that this polymorphism might function as a
teratogenic allele in spina bifida mothers, acting to
decrease the supply of reduced folate to the fetus. Their
data showed a significantly increased fraction of spina
bifida mothers compared to controls were DHFR 19 bp
deletion homozygotes, a finding not seen in individuals
with spina bifida or their fathers. This supported the
hypothesis that the DHFR deletion allele acts as a
teratogenic allele, i.e., it acts in the mother during
pregnancy to alter the development of the fetus,
contributing to the spina bifida phenotype (10).
However, two recent studies found the contrary, and
one even showed a protective effect to the mothers
(11,12)
We thus studied this mutation in Turkish spina bifida
patients and their mothers to determine whether there is
an association with the occurrence of NTD.

Materials and Methods
Patients
This case-control study included 69 MMC patients and
104 mothers who gave birth to NTD babies. These
individuals were simplex non-syndromic families and none
of the mothers had folate supplementation. These were
included consecutively on admission to the hospital. All
the MMC cases had lesions at the lumbosacral area. One
hundred sixty eight women, consecutively selected, who
admitted to the laboratory, were included as controls.
One hundred thirty-six newborns without MMC were also
included. All subjects were from Ankara, Turkey without
personal or family history of NTD.
Methods
Blood for mutation analysis was obtained after
provision of written informed consent by the parents and
DNA was extracted by conventional methods. Genotyping
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of the DHFR 19 bp deletion was analyzed by polymerase
chain reaction (PCR) amplification using three allele
specific primers (5’-CCACGGTCGGGGTACCTG-3’;
(Forward-2) 5’-ACGGTCGGGGTGGCCGACTC-3’ and
(Reverse) 5’–AAAAGGGGAATCCAG TCGG-3’) as
described previously. 113 bp product was separated on
10% polyacrylamide gel (10).

Results
Genotype distribution of DHFR gene 19 bp deletion of
intron-1 is given in Table. Case mothers and the patient
group demonstrated the distribution expected under
Hardy-Weinberg.
DHFR gene 19 bp deletion in homozygous state was
higher in the MMC group compared to control newborns
[(Odds Ratio 2.4 (CI 95% 0.95-6.08)]. It brought a 2.4fold risk [Odds Ratio 2.4 (CI 95% 1.04-5.6)] in NTD
mothers compared to controls.

Discussion
Previous data revealed that MTHFR 677 C-T
alteration did not increase the risk for the occurrence of
spina bifida in our population (4,5). The combination of
homozygous MTHFR 677T and homozygous DHFR gene
19 bp deletion was found only in one individual in
controls and mothers, but in none in the MMC group
(data not shown).
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The C677T allele of the MTHFR gene and some other
functional polymorphisms are reported as risk factors for
spina bifida in some populations. However, despite
extensive study, the genetic risk factors for spina bifida
are incompletely understood. Polymorphic alleles that
diminish bioavailability of reduced folate in the mother
during pregnancy could contribute to spina bifida in her
fetus, acting in the mother as teratogenic alleles. Johnson
et al. (10) (2004) reported a polymorphic 19 bp deletion
within intron-1 of DHFR, hypothesizing that DHFR
deletion allele might decrease DHFR expression, revealing
a risk for the spina bifida mothers who were found to
carry intron-1 19 bp homozygous deletion allele
compared to controls. However, two recent studies found
the contrary, and one even showed a protective effect to
the mothers (11,12). Our data is in concordance with
Johnson et al.’s hypothesis showing that NTD mothers
homozygous for 19 bp del have 2.4-fold greater risk
compared to the controls in our population.
DHFR gene 19 bp deletion homozygosity and other
possible mutations in the DHFR gene should be studied
further, especially in folate-supplemented mothers with
NTD recurrence. Until then, since about 75% of the NTDs
are preventable with folate supplementation in the
mother before conception, it is appropriate that folate
supplementation should be undertaken irrespective of
their genotypes.

Table. Distribution of DHFR -19 bp del in Turkish NTD mothers and patients.
DHFR -19 bp del

W/W

W / 19 bp del

Homozygous
19 bp del

n

Meningomyelocele
Controls (newborn)
Mothers
Controls (mothers)

69
136
104
168

n

%

n

%

n

%

28
61
40
81

40.57
44.8
38.46
48.2

30
66
49
77

43.5
48.5
47.1
45.8

11
9
15
10

15.94
6.6
14.42
5.9

Frequency of
19 bp del

37.6
30.8
37.9
28.8
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